Menu Search
Equities

Design Therapeutics Inc

DSGN:NSQ

Design Therapeutics Inc

Actions
  • Price (USD)5.62
  • Today's Change0.05 / 0.90%
  • Shares traded83.71k
  • 1 Year change+154.30%
  • Beta1.8366
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Design Therapeutics Inc's net income fell 5.61% from a loss of 63.31m to a larger loss of 66.86m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-17.02%
Return on equity-17.78%
Return on investment-17.64%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Design Therapeutics Inc fell by 5.30m. However, Cash Flow from Investing totalled 52.54m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 58.56m for operations while cash generated from financing totalled 724.00k.
Cash flow per share-0.8362
Price/Cash flow per share--
Book value per share4.46
Tangible book value per share4.46
More ▼

Balance sheet in USDView more

Design Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio34.61
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.